The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

Sadeleştirilmiş öğe sayfası
dc.contributor.authorYildirim, Hasan Cagri
dc.contributor.authorKutlu, Yasin
dc.contributor.authorMutlu, Emel
dc.contributor.authorAykan, Musa Baris
dc.contributor.authorKorkmaz, Mustafa
dc.contributor.authorYalcin, Selim
dc.contributor.authorSakalar, Teoman
dc.contributor.authorCelayir, Ozde Melisa
dc.contributor.authorKayikcioglu, Erkan
dc.contributor.authorAslan, Ferit
dc.contributor.authorHafizoglu, Emre
dc.contributor.authorAltintas, Yunus Emre
dc.contributor.authorKeskinkilic, Merve
dc.contributor.authorChalabiyev, Elvin
dc.contributor.authorCelebi, Abdussamet
dc.contributor.authorDursun, Bengu
dc.contributor.authorKapar, Caner
dc.contributor.authorOzen, Mirac
dc.contributor.authorAcar, Oemer
dc.contributor.authorDulgar, Ozgecan
dc.contributor.authorKut, Engin
dc.contributor.authorBiter, Sedat
dc.contributor.authorKus, Fatih
dc.contributor.authorAlmuradova, Elvina
dc.contributor.authorErdogan, Atike Pinar
dc.contributor.authorSaray, Seray
dc.contributor.authorGuven, Deniz Can
dc.contributor.authorSimsek, Eda Tanrikulu
dc.contributor.authorUskent, Necdet
dc.contributor.authorKemal, Yasemin
dc.contributor.authorCakar, Burcu
dc.contributor.authorAcikgoz, Ozgur
dc.contributor.authorKilickap, Saadettin
dc.contributor.authorAksoy, Sercan
dc.date.accessioned2025-10-16T15:13:45Z
dc.date.issued2024
dc.identifier.doi10.1007/s10147-023-02460-5
dc.identifier.otherWOS:001156854500001
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/5935
dc.publisherSPRINGER JAPAN KK
dc.sourceINTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
dc.subjectMale breast cancer
dc.subjectCDK4
dc.subject6 inhibitors
dc.subjectPalbociclib
dc.subjectRibociclib
dc.titleThe efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS